## Ali Judd

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8701586/publications.pdf

Version: 2024-02-01

		81839	102432
113	4,778 citations	39	66
papers	citations	h-index	g-index
116	116	116	5071
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, The, 2011, 11, 363-371.	4.6	345
2	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
3	Morbidity, Mortality, and Response to Treatment by Children in the United Kingdom and Ireland with Perinatally Acquired HIV Infection during 1996-2006: Planning for Teenage and Adult Care. Clinical Infectious Diseases, 2007, 45, 918-924.	2.9	194
4	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
5	Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. Journal of Medical Virology, 2003, 71, 49-55.	2.5	152
6	Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ: British Medical Journal, 2005, 330, 24-25.	2.4	145
7	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
8	Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. Aids, 2002, 16, F25-F31.	1.0	126
9	Methods to Recruit Hard-to-Reach Groups: Comparing Two Chain Referral Sampling Methods of Recruiting Injecting Drug Users Across Nine Studies in Russia and Estonia. Journal of Urban Health, 2006, 83, 39-53.	1.8	106
10	Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. Journal of Viral Hepatitis, 2008, 15, 250-254.	1.0	102
11	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet, The, 2011, 377, 1580-1587.	6.3	101
12	Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e309-e323.	4.7	99
13	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	3.9	98
14	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. Antiviral Therapy, 2009, 14, 1065-1074.	0.6	92
15	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
16	Drug-Related Mortality and Fatal Overdose Risk: Pilot Cohort Study of Heroin Users Recruited From Specialist Drug Treatment Sites in London. Journal of Urban Health, 2003, 80, 274-287.	1.8	87
17	Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction, 2004, 99, 621-633.	1.7	87
18	Mortality in perinatally <scp>HIV</scp> â€infected young people in <scp>E</scp> ngland following transition to adult care: an <scp>HIV Y</scp> oung <scp>P</scp> ersons <scp>N</scp> etwork ( <scp>HYPNet</scp> ) audit. HIV Medicine, 2014, 15, 239-244.	1.0	85

#	Article	IF	Citations
19	Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. Aids, 2009, 23, 597-604.	1.0	82
20	Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology, 2007, 36, 396-405.	0.9	79
21	Young People in the United Kingdom and Ireland with Perinatally Acquired HIV: The Pediatric Legacy For Adult Services. AIDS Patient Care and STDs, 2009, 23, 159-166.	1.1	76
22	Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction, 2004, 99, 1306-1314.	1.7	74
23	Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working?. American Journal of Public Health, 2001, 91, 38-42.	1.5	68
24	Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. International Journal of Drug Policy, 2003, 14, 25-43.	1.6	68
25	Differences in Factors Associated With Initial Growth, CD4, and Viral Load Responses to ART in HIV-Infected Children in Kampala, Uganda, and the United Kingdom/Ireland. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 384-392.	0.9	65
26	High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. Aids, 2006, 20, 2120-2123.	1.0	61
27	Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis. Journal of Viral Hepatitis, 2005, 12, 655-662.	1.0	55
28	Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 transitioning to adult care. Current Opinion in HIV and AIDS, 2016, 11, 477-486.	1.5	55
29	HIV diagnoses and missed opportunities. Results of the British HIV Association (BHIVA) National Audit 2010. Clinical Medicine, 2012, 12, 430-434.	0.8	47
30	Groin injecting in the context of crack cocaine and homelessness: From â€risk boundary' to â€acceptable risk'?. International Journal of Drug Policy, 2006, 17, 164-170.	1.6	45
31	Effects of Sex Work on the Prevalence of Syphilis Among Injection Drug Users in 3 Russian Cities. American Journal of Public Health, 2007, 97, 478-485.	1.5	45
32	Higher rates of tripleâ€elass virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
33	Measuring injecting risk behaviour in the second decade of harm reduction: a survey of injecting drug users in England. Addiction, 2000, 95, 1351-1361.	1.7	44
34	Injecting Equipment Sharing Among Injecting Drug Users in Togliatti City, Russian Federation. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 293-300.	0.9	44
35	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
36	Hyponatraemia in Premature Babies and Following Surgery in Older Children. Acta Paediatrica, International Journal of Paediatrics, 1987, 76, 385-393.	0.7	41

#	Article	IF	CITATIONS
37	HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. Aids, 2005, 19, 1207-1214.	1.0	41
38	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
39	Tenofovir Use in Human Immunodeficiency Virus-1–Infected Children in the United Kingdom and Ireland. Pediatric Infectious Disease Journal, 2009, 28, 204-209.	1.1	40
40	Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control study. Aids, 2010, 24, 525-534.	1.0	39
41	Early antiretroviral therapy in HIV-1-infected infants, 1996–2008. Aids, 2011, 25, 2279-2287.	1.0	37
42	Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. International Journal of STD and AIDS, 2005, 16, 749-754.	0.5	36
43	Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. Journal of the International AIDS Society, 2017, 20, 21577.	1.2	36
44	Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants. Aids, 2013, 27, 991-1000.	1.0	35
45	Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clinical Infectious Diseases, 2017, 64, 1105-1112.	2.9	35
46	Review article: directâ€acting antivirals for the treatment of HCV during pregnancy and lactation ― implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary Pharmacology and Therapeutics, 2019, 50, 738-750.	1.9	35
47	IDENTIFYING ALCOHOL-RELATED HARM IN YOUNG DRINKERS: THE ROLE OF ACCIDENT AND EMERGENCY DEPARTMENTS. Alcohol and Alcoholism, 1999, 34, 910-915.	0.9	34
48	Prevalence of sexual dysfunction in new heterosexual attenders at a central London genitourinary medicine clinic in 1998. Sexually Transmitted Infections, 2000, 76, 208-209.	0.8	32
49	Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antiviral Therapy, 2016, 21, 579-585.	0.6	32
50	Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. Aids, 2014, 28, 2395-2405.	1.0	31
51	Over a decade of syringe exchange: results from 1997 UK survey. Addiction, 2002, 97, 845-850.	1.7	30
52	Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. International Journal of Epidemiology, 2017, 46, dyw097.	0.9	30
53	HIV-1 DRUG RESISTANCE IN HIV-1-INFECTED CHILDREN IN THE UNITED KINGDOM FROM 1998 TO 2004. Pediatric Infectious Disease Journal, 2008, 27, 457-459.	1.1	29
54	Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non–HIV-Related Factors. Clinical Infectious Diseases, 2016, 63, 1380-1387.	2.9	29

#	Article	IF	Citations
55	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. PLoS Medicine, 2018, 15, e1002491.	3.9	29
56	Lopinavir Dosing in HIV-infected Children in the United Kingdom and Ireland. Pediatric Infectious Disease Journal, 2013, 32, 45-50.	1.1	27
57	Vertically acquired HIV diagnosed in adolescence and early adulthood in the United Kingdom and Ireland: findings from national surveillance. HIV Medicine, 2009, 10, 253-256.	1.0	26
58	Short- and Long-term Immunological and Virological Outcome in HIV-Infected Infants According to the Age at Antiretroviral Treatment Initiation. Clinical Infectious Diseases, 2012, 54, 878-881.	2.9	26
59	Adolescent transition among young people with perinatal HIV in high-income and low-income settings. Current Opinion in HIV and AIDS, 2018, 13, 236-248.	1.5	26
60	Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?. Journal of Viral Hepatitis, 2007, 14, 653-660.	1.0	22
61	Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?. Journal of Viral Hepatitis, 2007, 14, 584-591.	1.0	21
62	Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1040-1049.	0.6	21
63	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
64	Prevalence of Chlamydia trachomatis in young men in north west London. Sexually Transmitted Infections, 2000, 76, 273-276.	0.8	19
65	Episodic medication adherence in adolescents and young adults with perinatally acquired HIV: a within-participants approach. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 68-75.	0.6	19
66	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	2.9	18
67	Incidence of gonorrhoea diagnosed in GUM clinics in South Thames (west) region. Sexually Transmitted Infections, 1999, 75, 306-311.	0.8	17
68	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
69	Immediate antiretroviral therapy in young HIV-infected children. Current Opinion in HIV and AIDS, 2014, 9, 87-94.	1.5	16
70	Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study. Lancet HIV,the, 2015, 2, e530-e539.	2.1	16
71	Women injecting drug users in London: the extent and nature of their contact with drug and health services. Drug and Alcohol Review, 1998, 17, 267-276.	1.1	15
72	Improving survey methods in sero-epidemiological studies of injecting drug users: a case example of two cross sectional surveys in Serbia and Montenegro. BMC Infectious Diseases, 2009, 9, 14.	1.3	15

#	Article	IF	Citations
73	Sexual health of young people with perinatal HIV and HIV negative young people in England. PLoS ONE, 2018, 13, e0205597.	1.1	15
74	Tracking the transition of adolescents into adult HIV care: a global assessment. Journal of the International AIDS Society, 2017, 20, 21878.	1,2	14
75	Incidence of Pneumococcal and Varicella Disease in HIV-infected Children and Adolescents in the United Kingdom and Ireland, 1996–2011. Pediatric Infectious Disease Journal, 2015, 34, 149-154.	1.1	13
76	Characterizing the doubleâ€sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. Journal of the International AIDS Society, 2020, 23, e25447.	1,2	13
77	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
78	Outcomes after viral load rebound on first-line antiretroviral treatment in children with HIV in the UK and Ireland: an observational cohort study. Lancet HIV,the, 2015, 2, e151-e158.	2.1	12
79	Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand. Clinical Infectious Diseases, 2018, 66, 594-603.	2.9	12
80	HIV prevalence and risk behaviour among female injecting drug users in London, 1990 to 1996. Aids, 1999, 13, 833-837.	1.0	10
81	Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Current Opinion in HIV and AIDS, 2012, 7, 305-316.	1.5	9
82	Mortality and AIDSâ€defining events among young people following transition from paediatric to adult HIV care in the UK. HIV Medicine, 2021, 22, 631-640.	1.0	9
83	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk. Antiviral Therapy, 2012, 17, 599-603.	0.6	8
84	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. Clinical Infectious Diseases, 2019, 70, 404-415.	2.9	8
85	Prevalence of HIV infection in a multi-site sample of injecting drug users not in contact with treatment services in England. Aids, 2000, 14, 2413-2415.	1.0	8
86	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the International AIDS Society, 2022, 25, e25871.	1,2	8
87	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
88	Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project. BMC Infectious Diseases, 2016, 16, 654.	1.3	7
89	Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand. European Journal of Clinical Pharmacology, 2017, 73, 463-468.	0.8	7
90	Using Observational Data to Inform HIV Policy Change for Children and Youth. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S22-S26.	0.9	7

#	Article	IF	CITATIONS
91	Safety of Darunavir and Atazanavir in HIV-Infected Children in Europe and Thailand. Antiviral Therapy, 2016, 21, 353-358.	0.6	6
92	The cascade of care for children and adolescents with <scp>HIV</scp> in the <scp>UK</scp> and Ireland, 2010 to 2016. Journal of the International AIDS Society, 2019, 22, e25379.	1.2	6
93	Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiology and Drug Safety, 2014, 23, 321-325.	0.9	5
94	Self-harm in young people with perinatal HIV and HIV negative young people in England: cross sectional analysis. BMC Public Health, 2019, 19, 1165.	1.2	5
95	Outcomes of secondâ€ine antiretroviral therapy among children living with HIV: a global cohort analysis. Journal of the International AIDS Society, 2020, 23, e25477.	1.2	5
96	Young people in HIV care in Ukraine: a national survey on characteristics and service provision. F1000Research, 2019, 8, 323.	0.8	5
97	Young people in HIV care in Ukraine: a national survey on characteristics and service provision. F1000Research, 2019, 8, 323.	0.8	5
98	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
99	Who Gets Severe Gynecomastia Among HIV-infected Children in the United Kingdom and Ireland?. Pediatric Infectious Disease Journal, 2017, 36, 307-310.	1.1	4
100	Arterial Stiffness in a Cohort of Young People Living With Perinatal HIV and HIV Negative Young People in England. Frontiers in Cardiovascular Medicine, 2022, 9, 821568.	1.1	4
101	Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1448-1456.	0.6	3
102	Lipoatrophy/lipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland. PLoS ONE, 2018, 13, e0194132.	1.1	3
103	CD4 recovery following antiretroviral treatment interruptions in children and adolescents with HIV infection in Europe and Thailand. HIV Medicine, 2019, 20, 456-472.	1.0	3
104	Severe haematologic toxicity is rare in high risk HIVâ€exposed infants receiving combination neonatal prophylaxis. HIV Medicine, 2019, 20, 291-307.	1.0	3
105	Factors Associated With Nonadherence to Antiretroviral Therapy Among Young People Living With Perinatally Acquired HIV in England. Journal of the Association of Nurses in AIDS Care, 2020, 31, 574-586.	0.4	3
106	Labour pains: eliminating HCV in women and children. The Lancet Gastroenterology and Hepatology, 2021, 6, 150-151.	3.7	2
107	Children living with HIV in Europe: do migrants have worse treatment outcomes?. HIV Medicine, 2022, 23, 186-196.	1.0	2
108	Accuracy of perceptions of hepatitis B and C status. BMJ: British Medical Journal, 2000, 320, 512-512.	2.4	2

## Ali Judd

#	Article	IF	CITATIONS
109	Does community support help children take their ART?. The Lancet Child and Adolescent Health, 2017, 1, 160-161.	2.7	1
110	Reactivity of Routine HIV Antibody Tests in Children With Perinatally Acquired HIV-1 in England: Cross-sectional Analysis. Pediatric Infectious Disease Journal, 2019, 38, 146-148.	1.1	1
111	Care is required with cost effectiveness approach. BMJ: British Medical Journal, 2000, 321, 449-449.	2.4	1
112	The Prevalence of Darunavir-Associated Mutations in HIV-1-Infected Children in the Uk. Antiviral Therapy, 2012, 17, 599-603.	0.6	0
113	Epidemiology of hepatitis C virus in injecting drug users in England and Wales: implications for HCV drug therapy. Journal of Hepatology, 2001, 34, 127.	1.8	0